Key result
Pioglitazone lowers blood glucose without altering cardiac conduction or heart rate in diabetic rats.
Why the study?
Cardiovascular complications are the major cause of morbidity and mortality in diabetic patients, and the effects of pioglitazone on electrical conduction in diabetic hearts are unclear.
Does pioglitazone affect electrical conduction in the Goto-Kakizaki type 2 diabetic rat heart?
Does pioglitazone affect electrical conduction in the Goto-Kakizaki type 2 diabetic rat heart?
Answers are grounded in this paper and cite their sources.
Reassures on conduction safety in this diabetic rat model; leaves open translation to human ECG effects.
Cardiovascular complications are the major cause of morbidity and mortality in diabetic patients. Pioglitazone (PIO) is used for the treatment of type 2 diabetes mellitus and there is some evidence that it may improve ventricular function in diabetic patients. The effects of PIO on electrical conduction in the Goto-Kakizaki (GK) type 2 diabetic rat heart have been investigated. Transmitter devices were surgically implanted in GK and control rats aged 7 months. PIO at concentrations (2.5 to 20 mg/kg) was added to the drinking water. Animals received each concentration of PIO for 2 weeks. Bodyweight and blood glucose were measured periodically. The electrocardiogram was recorded throughout the study. Blood glucose was higher in GK rats compared to controls and was progressively reduced in GK rats treated with increasing concentrations of PIO. A modest reduction in heart rate was associated with a significant increase in PQ interval in GK rats compared to controls. Heart rate and PQ interval were not additionally altered by PIO. QRS complex and QT interval were not altered in GK compared to control or by PIO. In conclusion daily oral doses of PIO in the range 2.5 to 20 mg/ kg during a period of 14 weeks appeared to have little effect on electrical conduction in GK and control rat heart.
No takes yet. Share an insight, caveat, or question.
KA et al. (2015) studied Type 2 diabetes mellitus (animal model) (n=14). Pioglitazone vs. Vehicle control / baseline was evaluated on Electrical conduction parameters (heart rate, PQ, QRS, and QT intervals). Daily oral doses of pioglitazone over 14 weeks progressively reduced blood glucose but did not alter heart rate, PQ, QRS, or QT intervals in Goto-Kakizaki rats.
Synapse has enriched 10 related papers. Consider them for comparative context: